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ABSTRACT 
 
Background: Although evidence-based guidelines for the treatment of type 2 diabetes mellitus provide clear recommenda-
tions for initial therapy, evidence on an optimal treatment strategy after secondary failure is unclear. 
Purpose: To compare the efficacy of add-on therapy using basal insulin versus an additional oral antidiabetic agent in pa-
tients with type 2 diabetes and secondary failure. 
Data sources: We searched the following electronic databases from inception until June 2007: MEDLINE; EMBASE; Coch-
rane Central Register of Controlled Trials; Web of Science; Scopus; CINAHL; International Pharmaceutical Abstracts; Aca-
demic OneFile; PASCAL; Global Health Database; LILACS; HealthSTAR; PubMed. Reference lists of potentially relevant 
articles and clinical trial databases were searched, pharmaceutical manufacturers were contacted, and grey literature sources 
were sought. 
Study selection: Randomized controlled trials (RCTs) involving subjects with type 2 diabetes with secondary failure who 
were randomly assigned to receive additional basal insulin therapy (insulin glargine, detemir, or NPH [neutral protamine 
Hagedorn]) versus another oral antidiabetic agent from any class.  
Data extraction: Two reviewers independently screened articles, extracted data and assessed methodological quality. Our 
primary outcome was glycemic control measured by change in glycosylated hemoglobin (HbA1C) and the proportion of sub-
jects achieving a HbA1C value of ≤ 7%.  
Data synthesis: To compare overall efficacy between the 2 treatment strategies, change in HbA1C was pooled across studies 
using a random-effects model and weighted mean difference (WMD). Eleven RCTs, involving 757 participants with a median 
age of 56 and a median known duration of diabetes of 11 years, were included in our analysis. Insulin treatment demon-
strated a small but statistically significant improvement in HbA1C compared with the use of an additional oral agent as add-
on therapy (WMD -0.17; 95% CI [confidence interval] -0.33 to -0.02). 
Limitations: The use of surrogate outcomes and the short duration of the trials makes it impossible to gain information on 
long-term patient-oriented outcomes. The overall quality of the studies was low, primarily in view of inadequate blinding.   
Conclusions: Although add-on therapy using injected insulin shows a slight benefit over an additional oral antidiabetic agent, 
our results indicate that basal insulin therapy and the use of an oral agent as add-on therapy produce comparable results. 
Non-therapeutic differences must be considered in the choice of treatment strategies. More high-quality studies with ade-
quate safety data using more aggressive insulin titrations are needed. 
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OWERING  BLOOD  GLUCOSE  WAS  SHOWN  TO  
 decrease  the  risk  of  microvascular  complica-
tions in the United Kingdom Prospective Diabe-
tes  Study  (UKPDS)  trial.
1
  In  this  study,  patients  ran-
domly assigned to the intensive protocol (target fasting 
plasma glucose (FPG) < 6 mmol/L) showed a significant 
reduction  in  microvascular  complications  and  a  trend 
toward  reduced  macrovascular  complications.
1
  Mainly 
on the basis of evidence from the UKPDS and other ma-
jor diabetes clinical trials,
2,3
 several organizations have 
formulated  guidelines  with  clear  recommendations  for 
the initial therapy of type 2 diabetes.
4–6
 However, in view 
of the progressive nature of type 2 diabetes,
7 patients and 
their clinicians will inevitably need to intensify therapy 
to maintain glycemic control. The decision to intensify 
therapy after initial treatment with oral medication has 
been defined as “secondary failure.”8–10 Although clinical 
trial evidence conveys the importance of early and sus-
tained blood glucose control,
1,2,11
 the optimal strategy for 
patients in whom initial oral antidiabetic drug therapy 
has proven ineffective is not well defined. 
Current clinical practice guidelines
4–6 for type 2 dia-
betes recommend  the addition of either insulin or an-
other oral agent when monotherapy using an oral agent 
achieves  inadequate  control  (HbA1C  > 7%).  However,  it 
unclear which of these options is preferable. 
A randomized controlled trial (RCT) assessing the ef-
ficacy  of  intensive  glycemic  control  (HbA1C  < 6%) 
through  an  extensive  protocol  involving  titration  and 
the addition of various antidiabetic strategies, the Ac-
tion  to  Control  Cardiovascular  Risk  in  Diabetes 
(ACCORD) Trial (www.accordtrial.org) is currently un-
der way; the results, however, are not expected until at 
least  2010.  Previous  systematic  reviews  have  not  ex-
plored whether it is preferable to add insulin therapy or 
to add an additional oral agent in patients with secon-
dary failure. Goudswaard et al
12 focused on switching a 
patient’s  therapeutic  regimen  to  insulin  monotherapy 
versus  adding  insulin  to  oral  antidiabetic  agents.  Re-
views assessing combination therapy of insulin and oral 
antidiabetic agents have been limited to a specific class 
of  oral  antidiabetic  agents,  most  commonly  sulfony-
lureas,
13–15 and assessed whether combination therapy 
with  insulin  was  beneficial  compared  with  insuln 
monotherapy.  Moreover,  these  previous  reviews  pre-
date the launch of the newer long-acting insulins — in-
sulin glargine and detemir. 
The objective of this meta-analysis was to evaluate the 
evidence of the efficacy of adding basal intermediate or 
long-acting  insulin  versus  the  addition  of  another  oral 
antidiabetic agent in patients with type 2 diabetes whose 
current oral antidiabetic therapy was failing. 
 
Methods 
Search  strategy.  The search strategy was designed to 
capture the patient population, consisting of people with 
type 2 diabetes currently using any class of oral antidia-
betic therapy; the population problem, defined as current 
treatment failure; the intervention of insulin glargine, de-
temir  or  NPH  (neutral  protamine  Hagedorn);  and  the 
primary outcome measure of change in glycosylated he-
moglobin (HbA1C). Our search strategy was developed in 
consultation with a research librarian well versed in the 
conduct  of  systematic reviews  and  in  the  use  of  MeSH 
(MEDLINE subject headings) and key terms.   
The  MEDLINE-based  search  strategy  formed  the 
foundation  for  searching  in  other  databases.  We 
searched the following electronic bibliographic databases 
from  their  inception  until  June  2007:  MEDLINE, 
EMBASE, Cochrane Register of Conrolled Trials, Web of 
Science, Scopus, CINAHL, International Pharmaceutical 
Abstracts,  Academic  OneFile,  PASCAL,  Global  Health 
Database, LILACS, HealthSTAR, and PubMed. Other lit-
erature sources were also searched, including: reference 
lists  of  all  included  studies  and  relevant  narrative  re-
views;  clinical  trials  databases  (ClinicalTrials.gov,  Cen-
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terWatch  Clinical  Trials  Listing  Service,  and  Current 
Controlled  Trials);  OCLC  Proceedings  First  and  OCLC 
Papers  First  databases  to  identify  studies  presented  at 
conferences and proceedings; and Proquest and Index to 
Theses to identify relevant theses and dissertations. We 
contacted the  pharmaceutical companies producing in-
sulin  glargine  (Sanofi-Aventis),  insulin  detemir  (Novo 
Nordisk)  and  NPH  (Novo  Nordisk,  Lilly)  to  inquire 
about other published or unpublished studies.   
 
Selection of studies. Citations identified in the litera-
ture search were independently screened by two review-
ers  (JG,  SS)  to  select  potentially  relevant  articles.  The 
full  articles  from  this  list  were  retrieved  and  subse-
quently reviewed by 2 reviewers (JG, LB) for inclusion in 
the systematic review. Inter-rater agreement at this stage 
was  assessed  using  Cohen’s  kappa  statistic.  Disagree-
ments between reviewers were reconciled by consensus; 
a third-party intermediary was not required.  Reviewers 
were not blinded to the authors, journal, or publisher of 
the studies.  Non-English abstracts and articles were as-
sessed by one reviewer (SK).   
Studies were included if they had the following char-
acteristics: RCTs, whether parallel or crossover design; 
participants  inadequately  controlled  on  their  current 
oral antidiabetic regimen, defined as an HbA1c > 7% or a 
fasting plasma glucose (FPG) > 7 mmol/L; participants 
insulin naïve at baseline; subjects randomly assigned to 
receive the addition of either basal insulin therapy (insu-
lin glargine, detemir, or NPH) or another oral antidia-
betic  agent  from  any  class  (biguanide,  sulfonylurea, 
thiazolidinedione,  non-sulfonylurea  secretagogue,  or 
glucosidase inhibitor). We use the term “basal” to mean 
administration of an intermediate or long-acting insulin 
as 100% of daily insulin dose; specifically, these would 
be regimens using  NPH, glargine, or detemir.4 We felt 
that crossover trials were suitable for our clinical ques-
tion, as diabetes management is a chronic condition of 
which we do not expect a carry-over effect of treatment 
in respect to blood glucose levels. Data from crossover 
trials were entered as a parallel study.   
In addition  to the above criteria, studies  must have 
reported (or given the information to calculate) change 
in  HbA1C  (%)  from  baseline.  Glycemic  control  was  our 
primary outcome, measured by change in HbA1C and the 
proportion of individuals achieving an HbA1C ≤ 7%. Sec-
ondary  outcomes  included  change  in  FPG  (mmol/L), 
change in weight (kg) and the proportion of participants 
who experienced ≥ 1 hypoglycemic event as defined by 
the study investigators. 
 
Data  extraction  and  management.  Two  reviewers 
(JG, LB) independently extracted the data from all arti-
cles that met predefined eligibility criteria. Data were re-
corded  on  a  standardized  form,  and  all  discrepancies 
were  resolved by consensus. Both reviewers independ-
ently extracted data from 2 studies using a preliminary 
data extraction form. Minor revisions to the extraction 
form  were  made after   this  trial  period  to  provide the 
content  found  in  Textbox  1.  We  attempted  to  contact 
authors to verify, interpret and obtain missing data. In 
addition  to  extracting  data,  the  reviewers  assessed  the 
overall methodological quality of studies using the Jadad 
scale.
16 Methodological quality was assessed on the basis 
of information reported in the published article only. In 
addition,  the  scale  devised  by  Schulz  and  colleagues
17 
was used to assess allocation  of concealment. Funding 
sources for included studies were also considered. 
  If the mean change and its respective standard devia-
tion were missing, we calculated the mean change from 
baseline  by  subtracting  the  mean  baseline  HbA1C  from 
the mean HbA1C at the last follow-up date. Standard de-
viation  (SD)  was  calculated  using  standard  formulas,
18 
using a correlation coefficient of 0.5 to allow estimation 
of the combined SDs. In one study
19 we had to estimate 
the values of HbA1C and fasting plasma glucose from in-
spection of graphs, as the exact values were not included 
in the publication. We substituted the mean SD from the 
other studies that used an identical comparison agent.  
 
Data synthesis. We chose a random-effects model for 
our  meta-analysis,  as  this  is  more  conservative  than  a 
fixed-effects model and therefore less likely to overesti-
mate treatment effects.
20 Statistical, clinical, and meth-
odological heterogeneity were assessed to determine the 
appropriateness  of  pooling  data  across  studies.  We 
evaluated statistical heterogeneity using the I
2 statistic. A 
value of I
2 greater than 50% was considered indicative of 
significant heterogeneity.
18 We recognized the potential 
for variability in key clinical characteristics such as dura-
tion of diabetes, baseline  HbA1C, and age; however,  we 
used  the  method  described  by  Tobias
21  to  explore  the 
impact of each study on the overall summary effect. 
We further explored sources of potential heterogeneity 
through subgroup and sensitivity analyses. Subgroups de-
fined a priori included stratification by the type of insulin R e s e a rc h                                                                                                                                                   G a m b l e   et al 
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(NPH, glargine, detemir) and the comparative oral agent 
(metformin,  thiazolidinedione,  acarbose).  Sensitivity 
analyses were performed on the following factors, defined 
a priori: fixed-effects versus random-effects model; paral-
lel versus crossover design; and duration of follow-up. 
All continuous variables (changes in HbA1C, FPG, and 
weight)  were  expressed  using  a  weighted  mean  differ-
ence  (WMD) and  95% confidence interval (CI). All di-
chotomous  outcomes  (proportion  of  subjects  achieving 
HbA1C ≤ 7%, and proportion of subjects experiencing ≥ 1 
hypoglycemic event) were expressed using relative risk 
(RR) and 95% CI. We chose RR as a measure of effect, 
given considerations of consistency and interpretability. 
Publication bias was assessed by examining the symme-
try of a funnel plot, where sample size is plotted against 
the treatment effect. A funnel plot was inspected for our 
primary outcome only, in view of the small number of 
studies that addressed our secondary outcomes. 
Results 
Search  strategy.  Our  search  strategy  identified  1234 
unique  citations,  and  an  additional  26  citations  were 
identified from grey literature sources (Fig. 1). Screening 
of title, abstracts, and  keywords identified 54 citations 
potentially relevant to the review question, and the full 
text for these studies was retrieved. Seven non-English 
articles were assessed by 1 reviewer (SK), who found that 
none met the eligibility criteria. Two reviewers assessed 
the remaining 47 potentially relevant articles and found 
that 12 studies met the eligibility criteria independently 
(kappa  =  0.74).  The  reviewers  arrived  at  a  consensus 
that 11 studies met all of the eligibility criteria.  
Included studies. Seven studies used a parallel design; 
4 studies22–25 used a crossover design. Crossover studies 
tended to have smaller sample sizes, contributing 119 to 
a total of 757 participants. Trial duration ranged from 12 
weeks to 1 year of follow-up. Sample sizes ranged from 
12  to  219  participants.  Three  studies  used  insulin 
glargine,26–28 7 studies used NPH insulin,22–25,29,30 and 1 
study did not specify the type of insulin.19 Five studies 
used a thiazolidinedione (n = 1 for pioglitazone and n = 4 
for rosiglitazone),26–30 5 studies used metformin,19,23–25,31 
and 1 study used acarbose22 as comparison agents. Base-
line HbA1C ranged from 8.8% to 11.2 %.  
  The  overall  quality  of  the  studies  was  low  (Jadad 
range 0–2), and only 1 study adequately described the al-
location  concealment  method.
30  One  study
22  was  de-
described as double-blinded; this was misleading, as the 
insulin arm was not blinded, and only the acarbose arm 
was masked with a placebo. Three studies
27,29,31 explicitly 
stated that they were “open label” studies. The average 
percentage of dropouts per study was 13% of the number 
of subjects randomly assigned to a study arm. Reasons 
for dropouts were given in all studies, except the 2 that 
had no dropouts.
25,28 Although 2 studies described an in-
tention-to-treat analysis,
27,30 in fact no study performed 
an intention-to-treat analysis.  
Six studies were sponsored by a pharmaceutical com-
pany.
26–29,31 Baseline clinical and demographic data for 
each study are listed in Table 1. Most studies did not ex-
plicitly  state  their  primary  outcome.  In  the  study  by 
Rosenstock  and  colleagues
27  the  primary  outcome  was 
identical to that of our systematic review: glycemic con-
trol measured using HbA1C.  
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Outcomes. To compare the overall efficacy of the two 
treatment options — addition of basal insulin versus an-
other  oral  antidiabetic  agent  —  outcome  results  from 
each study were pooled and an overall summary measure 
of effect was calculated. When all studies were pooled, 
the addition of basal insulin demonstrated a statistically 
significant  improvement  in  HbA1C  in  comparison  with 
the use of an oral agent as add-on therapy, but this dif-
ference  was  not  clinically  significant  (WMD  0.17;  95% 
CI -0.33  to  -0.02)  (see  Appendix  1  for  Forest  plots  of 
meta-analyses). The pooled analyses of patients achiev-
ing HbA1c ≤ 7% favoured the addition of insulin; how-
ever,  this  finding  did  not  reach  statistical  significance 
(RR 1.10; 95% CI 0.80–1.52). A third measure of glyce-
mic control was change in FPG from baseline, where an 
improvement  in  the  insulin  arm  versus  the  oral  agent 
arm was found (WMD -1.29; 95% CI -1.61 to -0.98). With 
respect to adverse events, more patients experienced at 
least one hypoglycemic event in the insulin group than in 
the oral agent group (RR 1.42; 95% CI 1.11–1.80). Weight 
gain was not pooled into an overall meta-analysis in view 
of the significant heterogeneity among studies.  
Results  were  categorized  into  clinically  meaningful 
subgroups according to the  type  of insulin used. Eight 
studies compared a once-daily injection of NPH versus 
an oral antidiabetic as add-on therapy.
19,22–25,29–31 Two of 
these studies used a thiazolidinedione,
29,30 5 studies used 
metformin
19,23–25,31 and 1 study used acarbose
22 as a com-
parator.  No  differences  between  groups  were  demon-
strated  for  overall  glycemic  control  as  measured  by 
change in HbA1C or proportion achieving an HbA1C ≤ 7%. 
A  greater  change  in  FPG  was  observed  in  the  NPH 
group  than  in  the  oral  therapy  group  (WMD  -1.64; 
95% CI 2.05 to -1.22). The proportion of participants who 
experienced a hypoglycemic event was higher in the NPH 
treatment group (RR 1.89; 95% CI 1.16–3.10), as was the 
change in weight in kilograms from baseline (WMD 1.19; 
95%  CI  0.61–1.76).  As  expected,  when  NPH  was  com-
pared with metformin only, even more weight gain was 
seen in the NPH group (WMD 1.29; 95% CI 0.62–1.96).  
 Three  studies  compared  the  addition  of  insulin 
glargine to an oral agent.
26–28 Rosiglitazone was the only 
oral agent used in all 3 studies. Glycemic control did not 
differ significantly between groups, although the point 
estimates favour the addition of insulin glargine for both 
change in HbA1C (WMD -0.13; 95% CI -0.31 to 0.06) and 
the proportion of subjects achieving a target HbA1C ≤ 7% 
(RR  1.22;  95%  CI  0.76–2.76).  A  significant  difference 
was  seen  in  favour  of  insulin  for  change  in  FPG 
(WMD 1.03; 95% CI -1.09 to -0.97) as well as weight gain 
(WMD -1.30; 95% CI -1.41 to -1.19). No difference was 
demonstrated between groups with respect to hypogly-
cemia (RR 1.29; 95% CI 0.98–1.71).  
Sensitivity  analyses,  using  a  fixed-effects  model, 
stratification by study design, or stratification by study 
duration, did not result  in a substantial change in the 
Textbox 1: Data extraction 
General  
•  study identifier 
•  name of reviewer 
•  date of extraction 
•  bibliographic source 
Study method 
•  design 
•  method of randomization 
•  length of study 
•  number lost to follow up 
•  number of withdrawals/dropouts 
•  reasons for withdrawal 
•  inclusion/exclusion criteria 
•  setting and location 
•  funding source 
Population  
•  sample size 
•  age and gender 
•  current oral antidiabetic regimen 
•  baseline HbA1c (%) 
•  baseline body mass index (kg/m2) and/or weight (kg) 
•  baseline fasting plasma glucose (mmol/L) 
•  diabetes duration at baseline 
Intervention 
•  type of insulin 
•  dose 
•  time of daily injection 
•  duration of therapy 
Comparison 
•  type of oral antidiabetic agent 
•  dose, frequency 
•  duration of therapy 
Outcomes  
•  primary outcomes stated 
•  change or follow up HbA1c 
•  change or follow up fasting glucose 
•  definition and number of hypoglycemic episodes  
•  change or follow-up weight 
Analysis 
•  intention-to-treat or per protocol 
• how authors dealt with missing data R e s e a rc h                                                                                                                                                   G a m b l e   et al 
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magnitude or direction of the summary effect. To test the 
robustness of our summary measure of effect for change 
in HbA1C, we used the method developed by Tobias,
21 by 
which  each  study  is  omitted  and  the  summary  effect 
measure is compared with the original result. The WMD 
did  not  change  by  more  than  10%,  with  the  exception 
that when the study by Rosenstock and colleagues
27 was 
omitted the WMD changed by 28% in favour of insulin 
treatment.  The  possibility  of  publication bias  was sug-
gested by asymmetry in the funnel plot. 
 
Discussion 
Management of type 2 diabetes mellitus is multifaceted, 
incorporating blood glucose, blood  pressure, lipid, and 
weight  control.  Although  guidelines  recommend  tight 
glucose control to reduce the risk of microvascular com-
plications,
4–6 many patients remain above recommended 
glycemic targets.
32 The progressive nature of type 2 dia-
betes further exacerbates the difficulty in achieving and 
maintaining glycemic control.
33 The objective of this re-
view was to evaluate the efficacy of 2 different treatment 
strategies in people with type 2 diabetes in whom initial 
oral  antidiabetic  therapy  had  failed.  We  compared  the 
addition of a basal insulin injection with the addition of 
another oral antidiabetic agent.  
The  results  of  this  systematic  review  indicate  that, 
when used as add-on therapy, basal insulin therapy and 
an oral agent achieve comparable glycemic control. Al-
though insulin showed a statistically significant benefit, 
the difference was small and of limited clinical impor-
tance. The clinical impact of a 0.17% reduction in HbA1C 
associated  with  insulin  therapy  versus  the  addition  of 
oral therapy must be viewed in light of the absence of 
large-scale quality trials. The 95% CI showed  potential 
benefit ranging from a 0.02% to a  0.33% reduction  in 
HbA1C.  We  reported  pooled  estimates  of  the  WMD  in 
change in HbA1C from baseline, comparing insulin and 
oral  agent  treatment  according  to  the  type  of  insulin 
agent  used.  Although  the  overall  pooled  estimate  fa-
voured the addition of basal insulin, analysis stratified 
Table 1: Study characteristics 
Study 
(year), 
type  N* 
Insulin 
type  Oral agent 
Diabetes 
duration 
(yrs) 
HbA1C 
(%) 
Age 
(yrs)  % M/F  BMI  OAD 
Jadad 
score 
Funding 
source 
Aljabri
29 
(2004), P 
62/58  NPH  Pioglitazone  10  9.9  58  60/40  25.5  Met + SU or 
Met + nateg-
linide 
2  Eli Lilly† 
Bastyr
31 
(2000), P 
135/114  NPH  Metformin  8  10.2  57  60/40  28.4  Glyburide  1  Eli Lilly 
Klein
19 
(1991) 
50/35  NR  Metformin  12  NR  67  24/76  NR  Glibenclamide  1  Unclear 
Ko
30 ‡ 
(2006), P 
112/104  NPH  Rosiglitazone  13  9.9  58  56/44  24.9  SU or Met + 
SU 
1  Internal 
López-
Alverenga
22 
(1999), C 
37/29  NPH  Acarbose  10  11.2  53  28/72  27.3  Chlorpropa-
mide + Met 
1  Bayer 
Rey-
nolds
26‡ 
(2007), P 
40/35  Glargine  Rosiglitazone  11  9.0  61  100/0  31.6  Met + SU  1  GSK† 
Rosen-
stock
27 
(2006), P 
219/216  Glargine  Rosiglitazone  8  8.8  56  52/48  34.1  Met +SU  1  Aventis 
Triplitt
28 ‡ 
(2006), P 
20/20  Glargine  Rosiglitazone  8  9.3  48  40/60  30.2  Met +SU  0  Aventis 
Trischitta
23 
(1992), C 
20/16  NPH  Metformin  12  10.2  43  35/65  NR  Glyburide  1  Unclear 
Trischitta
24 
(1998), C 
50/45  NPH   Metformin  13  9.1  56  24/76  27.8  Glibenclamide  1  Unclear 
Vingeri
25 
(1991), C 
12/12  NPH  Metformin  12  NR  52  NR  NR  Glyburide  1  Unclear 
* randomized / analyzed; M/F = male/female; BMI = body mass index (kg/m
2); OAD = oral antidiabetic therapy;  P = parallel design; C = crossover design; NPH =  neutral  
protamine Hagedorn; Met = metformin; SU = sulfonylurea; NR = not reported; GSK = GlaxoSmithKline. 
The study that did not report the type of insulin (Klein
19) was analysed with the NPH studies. 
† Sponsor had no role in study design, analysis, or involvement in manuscript preparation.  ‡ Additional information was obtained from the authors.  R e s e a rc h                                                                                                                                                   G a m b l e   et al 
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by  insulin  type  to  obtain  an  indirect  comparison
34 
showed no apparent difference between NPH or glargine 
in comparison with the addition of an oral antidiabetic 
agent. Another outcome of interest with respect to gly-
cemic control was the number of patients in each treat-
ment group who achieved the target HbA1C ≤ 7%.
4,5 The 
small  number  of  patients  who  achieved  an  optimal 
HbA1C was likely related to the conservative dosing of in-
sulin. A much larger magnitude of effect was observed 
with  respect  to  change  in  FPG,  but  this  might  be  ex-
pected insofar as insulin dosing was titrated on the basis 
of FPG levels in all of the studies. In view of the signifi-
cant  heterogeneity  between  NPH  and  glargine  groups, 
the magnitude of effect must be considered in context. 
Insulin glargine was generally used as a third-line agent, 
whereas NPH was added as a second-line agent. There-
fore, the magnitude of effect may have been influenced 
by  other  factors,  such  as  differences  in  postprandial 
blood  glucose control,  which could account for the di-
minished effect observed in the change in HbA1C.
27  
The relative safety of the 2 treatment strategies was 
evaluated  using  2  secondary  outcomes:  proportion  of 
subjects  experiencing  ≥ 1  hypoglycemic  event,  and 
change in weight. As expected, hypoglycemic events were 
more frequent in the insulin group than in the oral agent 
group. This appears to have been driven mostly by the 
large  number  of  studies  that  used  metformin  as  the 
comparison agent. The magnitude of effect is diminished 
and is statistically non-significant when only studies us-
ing  a  thiazolidinedione  are  considered.  Overall,  there 
was no difference in weight gain when insulin versus an 
oral agent was used as add-on therapy. The significant 
heterogeneity  observed  (I
2  92.8%;  p  < 0.001)  is  ex-
plained  in  part  by  subgroup  analysis.  Of  the  7  studies 
that  used  NPH  and  reported  weight  as  an  outcome 
measure, 4 used metformin as the comparison oral agent 
and  showed  a  non-significant  increase  in  weight  gain 
among  the  the  NPH  users  (WMD  1.29;  95%  CI  0.62–
1.96). This is consistent with metformin use in general, 
which is advocated for overweight patients.
4 In the insu-
lin glargine subgroup, insulin users experienced signifi-
cantly less weight gain than those who used rosiglitazone 
as an add-on agent (WMD -1.30; 95% CI -1.41 to -1.19).  
 
Limitations. Several limitations should be considered 
in  the  interpretation  of  our  results.  First,  the  overall 
quality of the studies included in the meta-analysis was 
poor, as indicated by their average Jadad score. We iden-
tified  several  recurring  problems  of  methodology.  For 
example,  although  all  studies  used  random  allocation, 
the process of randomization and concealment was not 
adequately described. Moreover, the lack of blinding was 
an important limitation across all studies. Proper blind-
ing would require a double-dummy design whereby par-
ticipants  would  administer  an  injection  and  an  oral 
tablet concurrently. Second, follow-up times were rela-
tively short, considering that people with type 2 diabetes 
receive treatment for the rest of their lives. Two studies 
had a follow-up of 1 year.
19,30 However, the 2 treatment 
groups might not show comparable efficacy after 2, 5, or 
10 years. Longer follow-up times would increase the ex-
ternal validity of the results. A third limitation is that our 
primary  outcomes  are  surrogate  markers  and  lack  in-
formation on long-term outcomes, such as microvascular 
or  cardiovascular  events.  A  fourth  consideration  con-
cerns the limit to which a triple oral therapy can lower 
HbA1C. The addition of a third oral agent is unlikely to 
decrease  HbA1C  levels  by  greater  than  1.5%  to  2.0%; 
therefore, insulin may be a more appropriate option for 
those whose diabetes is very poorly controlled (> 9.5%) 
with  secondary  oral  antidiabetic  therapy.  Evidence  for 
this exists in the findings of Rosenstock and colleagues,
27 
which show that the glucose-lowering benefit of insulin 
glargine, as measured by FPG, was greater when baseline 
HbA1C  was  ≥ 9.5%.  A  fifth  limitation  is  the  absence  of 
data  for  secondary  outcomes.  Hypoglycemic  event  re-
porting was inconsistent, and definitions of hypoglyce-
mia were rare (n = 3).
27–29 Similarly, reporting on weight 
change was inconsistent between studies. Consistent re-
porting of other side-effects such as edema or pain at the 
injection site would aid in the applicability of the results.  
Although every effort was made to minimize biases in 
the review process, potential biases still exist. These biases 
were limited the involvement of 2 independent reviewers 
involved at each major stage in the review process. Publi-
cation bias was suggested by asymmetry observed on the 
funnel plot, although other sources of bias, including se-
lection bias, true heterogeneity, data irregularities, arte-
fact, or chance may explain this asymmetry.
35  
The results of this systematic review are relevant for 
clinicians working  with  patients with  poorly controlled 
type 2 diabetes  who are using either a sulfonylurea  as 
monotherapy  or  in  combination  with  metformin.  The 
choice of treatment regimens for add-on therapy should 
be evaluated in light of current HbA1C levels and the risk 
of hypoglycemia.  Non-therapeutic reasons such as cost R e s e a rc h                                                                                                                                                   G a m b l e   et al 
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and patient preference or adverse effects should be given 
adequate weight in view of the small magnitude of bene-
fit observed for insulin use as add-on therapy. The opti-
mal strategy for adding basal insulin therapy to an oral 
antidiabetic regimen remains to be demonstrated. More 
rigorous  studies  are  required  to  establish  the  ideal 
treatment strategy for people with type 2 diabetes expe-
riencing secondary failure on oral antidiabetic therapy.  
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Appendix 1: Forest plots 
 
 
 
Forest plot 1: Change in HbA1c (%) 
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Forest plot 3: Change in fasting plasma glucose (mmol/L)  
 
 
 
Forest plot 4: Proportion of study participants who experienced one or more hypoglycemic events 
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Forest plot 5: Weight change (kg) 
 
 
Appendix 2: MEDLINE final search strategy 
 
  1. Drug Therapy, Combination/ 
 2. exp Hypoglycemic Agents/ 
 3. exp Sulfonylurea Compounds/ 
 4. exp Biguanides/ 
 5. exp Glucosidases/ 
 6. Thiazolidinediones/ 
 7. sulfonylurea$.mp. 
 8. sulphonylurea$.mp. 
 9. biguanide$.mp. 
10. (thiazolidinedione$ or TZD?).mp. 
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12. secretagogue$.mp. 
13. glimepiride.mp. 
14. amaryl.mp. 
15. gliclazide.mp. 
16. diamicron.mp. 
17. glyburide.mp. 
18. glibenclamide.mp. 
19. diabeta.mp. 
20. metformin.mp. 
21. glucophage.mp. 
22. acarbose.mp. 
23. alpha glucosidase inhibitor?.mp. 
24. pioglitazone.mp. 
25. Actos.mp. 
26. rosiglitazone.mp. 
27. Avandia.mp. 
28. tolbutamide.mp. 
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30. 93479-97-1.rn. 
31. 111025-46-8.rn. 
32. 122320-73-4.rn. 
33. 657-24-9.rn. 
34. OAD.mp. 
35. oral hypoglyc?emi$ agent$.mp. 
36. oral antidiabet$ agent.mp. 
37. *Diabetes Mellitus, Type 2/dt [Drug Therapy] 
38. or/1-37 
39. exp "Outcome Assessment (Health Care)"/ 
40. (treatment adj (outcome or failure)).mp. 
41. insulin-naive.mp. 
42. OHA failure.mp. 
43. ((suboptimal$ or poor$ or glyc?emic or diabet$) adj contro?l$).mp. 
44. or/39-43 
45. Hemoglobin A, Glycosylated/ 
46. (Alc or A1c).mp. 
47. HbA1c.mp. 
48. GHb.mp. 
49. (hemoglobin or haemoglobin).mp. 
50. (glycosylated or glycated).mp. 
51. HbA1.mp. 
52. or/45-51 
53. clinical trial.pt. 
54. randomi?ed.ti,ab. 
55. placebo.ti,ab. 
56. dt.fs. 
57. randomly.ti,ab. 
58. trial.ti,ab. 
59. groups.ti,ab. 
60. or/53-59 
61. animals/ 
62. humans/ 
63. 61 not (61 and 62) 
64. 60 not 63 
65. glargine.mp. 
66. detemir.mp. 
67. ((add-on or "add on") adj3 therap$).mp. 
68. Insulin, Isophane/ 
69. Insulin, Long-Acting/ 
70. isophane.mp. 
71. (long acting or longacting or long-acting).mp. 
72. NPH.mp. 
73. nph insulin.mp. 
74. neutral protamine hagedorn.mp. 
75. 53027-39-7.rn. 
76. or/65-75 
77. and/38,44,52,64,76 
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